Agilon Health (NYSE:AGL) Price Target Raised to $1.50

Agilon Health (NYSE:AGL) had its target price lifted by Wells Fargo & Company from $1.00 to $1.50 in a research note published on Friday morning,Benzinga reports. Wells Fargo & Company currently has an overweight rating on the stock.

AGL has been the topic of several other reports. Barclays decreased their price target on shares of Agilon Health from $1.00 to $0.50 and set an “underweight” rating on the stock in a research note on Friday. BTIG Research reaffirmed a “neutral” rating on shares of Agilon Health in a report on Friday, December 12th. Royal Bank Of Canada upgraded shares of Agilon Health from a “hold” rating to a “moderate buy” rating in a research report on Wednesday, December 3rd. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Agilon Health in a research report on Wednesday, January 21st. Four equities research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, Agilon Health has a consensus rating of “Hold” and an average target price of $2.60.

Agilon Health Price Performance

Agilon Health stock opened at $0.59 on Friday. The company has a market capitalization of $243.94 million, a price-to-earnings ratio of -0.62 and a beta of 0.11. The company has a current ratio of 1.02, a quick ratio of 1.02 and a debt-to-equity ratio of 0.12. Agilon Health has a 12 month low of $0.34 and a 12 month high of $6.08. The stock’s 50 day moving average is $0.71 and its 200-day moving average is $0.85.

Agilon Health (NYSE:AGL) last released its quarterly earnings results on Wednesday, February 25th. The company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.27) by ($0.19). Agilon Health had a negative return on equity of 120.82% and a negative net margin of 6.60%.The firm had revenue of $1.57 billion for the quarter, compared to analyst estimates of $1.46 billion. Equities research analysts expect that Agilon Health will post -0.59 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the company. Wealthcare Advisory Partners LLC bought a new stake in Agilon Health during the third quarter worth $26,000. LPL Financial LLC increased its stake in shares of Agilon Health by 213.4% in the 4th quarter. LPL Financial LLC now owns 44,055 shares of the company’s stock valued at $30,000 after purchasing an additional 30,000 shares during the last quarter. Arrowpoint Investment Partners Singapore Pte. Ltd. acquired a new position in shares of Agilon Health during the 2nd quarter worth $31,000. Krilogy Financial LLC bought a new stake in shares of Agilon Health during the 4th quarter worth $34,000. Finally, CIBC Bancorp USA Inc. acquired a new stake in Agilon Health in the third quarter valued at about $34,000.

Agilon Health News Summary

Here are the key news stories impacting Agilon Health this week:

• Positive Sentiment: Wells Fargo upgraded AGL to “overweight” and raised its price target to $1.50 (from $1.00), implying meaningful upside from current levels — a bullish analyst signal that can support buying interest. Benzinga
• Neutral Sentiment: Q4 results were mixed: revenue beat estimates ($1.57B vs. ~$1.46B) but EPS missed materially (reported ($0.46) vs. consensus ($0.27)), leaving investors weighing top-line strength against profitability issues. Earnings Release/Transcript
• Neutral Sentiment: Management outlined a 2026 target (~$5.5B revenue and breakeven adjusted EBITDA) as part of a transformation plan — a constructive medium‑term goal but one that may be viewed skeptically given recent misses and execution risk. Seeking Alpha
• Negative Sentiment: Company guidance was lower than Street expectations (FY revenue midpoint and Q1 revenue below consensus), which increases downside risk as analysts rework models and investor confidence is tested. Seeking Alpha
• Negative Sentiment: Barclays cut its price target to $0.50 and moved to “underweight,” signaling additional analyst pessimism and potential further selling pressure. Benzinga
• Negative Sentiment: Multiple law firms have filed or are soliciting lead-plaintiff interest in securities class actions alleging fraud tied to Agilon, with several deadline reminders for March 2, 2026 — legal overhang and potential litigation costs are weighing on sentiment. GlobeNewswire

About Agilon Health

Agilon Health (NYSE: AGL) is a healthcare company that partners with independent primary care physicians to deliver value-based care for Medicare beneficiaries. Through risk-sharing arrangements, Agilon assumes financial responsibility for patient populations, enabling physicians to focus on preventive and proactive health management. The company provides the administrative, clinical and operational infrastructure needed to support comprehensive care delivery.

Agilon’s platform encompasses data analytics, care management, patient engagement tools and population health programs.